SKB BIO-B (06990) announced multiple innovative drug research results at the European Oncology Congress in 2025.
Colembato biology-B (06990) announced that the company has been exhibited in Berlin, Germany from October 17th to 21st...
SKB BIO-B (06990) announced that the company has presented multiple clinical research findings at the 2025 European Society for Medical Oncology (ESMO) Congress held in Berlin, Germany from October 17th to 21st. The research covers targeted antibody-drug conjugates (ADCs) including sacituzumab govitecan (Trodelvy) targeting TROP2, ado-trastuzumab emtansine (Kadcyla) targeting HER2, and data related to SKB315, an ADC targeting Claudin18.2 (CLDN18.2).
Related Articles
HK Stock Market Move | JACOBIO-B(01167) rose more than 7% during trading hours as the company sold non-core projects and focused on the core pipeline of innovative cancer drugs.
Tianfeng: AI reshapes the storage cycle logic, driven by dual technology demands.
Guotai Haitong: Stabilize game business foundation, invest extensively in diversified empowerment, first give NETDRAGON (00777) a "buy" rating, with a target price of HK$16.7.
HK Stock Market Move | JACOBIO-B(01167) rose more than 7% during trading hours as the company sold non-core projects and focused on the core pipeline of innovative cancer drugs.
Tianfeng: AI reshapes the storage cycle logic, driven by dual technology demands.
Guotai Haitong: Stabilize game business foundation, invest extensively in diversified empowerment, first give NETDRAGON (00777) a "buy" rating, with a target price of HK$16.7.
RECOMMEND
